Piotr Pierzyński; Oliver Pohl; Line Marchand; Shari Mackens; Ulrike Lorch; Jean-Pierre Gotteland; Christophe Blockeel
Tag: Nolasiban
Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials
G Griesinger, C Blockeel, P Pierzynski, H Tournaye, H Višňová, A Humberstone, P Terrill, O Pohl, E Garner, J Donnez, E Loumaye
Human Reproduction, Volume 36, Issue 4, April 2021, Pages 1007–1020
Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers
Jörg Täubel, Ulrike Lorch, Christopher S. Spencer, Anne Freier, Dorothée Camilleri, Dilshat Djumanov, Georg Ferber, Line Marchand, Jean-Pierre Gotteland & Oliver Pohl
The use of nolasiban, a novel oxytocin receptor antagonist, prior to embryo transfer: does it help?
Ernest Loumaye, MD, PhD
19th World Congress of Gynecological Endocrinology (On Line Congress 2-5 December 2020, available until 15 April 2021)
Abstract on p. 39 – part of SYMP19: Recent development in IVF
Gynecological and Reproductive Endocrinology and Metabolism 2020; Supplement 1 – Book of abstracts
The effect of the oral oxytocin antagonist, nolasiban, on pregnancy rates in women undergoing embryo transfer following IVF
Georg Griesinger, MD, PhD; Jacques Donnez, PhD, MD; Andrew Humberstone, PhD; Paul Terrill, PhD; Oliver Pohl, DVM, MPH, MSc; Elizabeth Garner, MD, MPH; Ernest Loumaye, MD, PhD
ASRM 2020 Virtual Congress, October 2020
Poster session, abstract – Poster P. 482, page e303
Fertility and Sterility, Volume 114, No. 3, Supplement, September 2020, Poster P-482, page e303
The mechanism of action of oxytocin receptor antagonists (OTRan) in ART – a study of nolasiban on biomarkers of uterine receptivity in healthy female volunteers
O. Pohl, L. Marchand, P. Pierzyński, C. Blockeel, S. Mackens, U. Lorch, J.P. Gotteland
ESHRE 36th Virtual Annual Meeting, 5-8 July 2020
Human Reproduction, Volume 35, Issue Supplement_1, July 2020, on pages i83–i84
Babies Born Following Administration of Nolasiban Before Embryo Transfer (ET) After IVF: Neonatal and Infant Development Outcomes From a Double-Blind, Placebo-Controlled, Clinical Trial
Humberstone A., Terrill P., Macgregor L., Loumaye E.
ASRM 2019 Scientific Congress & Expo, 12-16 October 2019, Philadelphia, PA
Fertility and Sterility Vol. 112, No. 3, Supplement, September 2019. Abstract on pages e7-e8.
Nolasiban (OBE001) —Assisted Reproductive Technology
Our Pipeline
Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium
Sung Hye Kim, Lucia Riaposova, Hauwa Ahmed, Oliver Pohl, André Chollet, Jean-Pierre Gotteland, Aylin Hanyaloglu, Phillip R. Bennett & Vasso Terzidou
A Placebo-Controlled, Randomized, Double-Blind, Phase 3 Study Assessing Ongoing Pregnancy Rates After Single Oral Administration of a Novel Oxytocin Receptor Antagonist, Nolasiban, Prior to Single Embryo Transfer
Visnova H., Tournaye H. J., Humberstone A., Terrill P., Macgregor L., Loumaye E.
ASRM 2018, 6-10 October 2018, Denver, CO
Fertility and Sterility September 2018 Volume 110, Issue 4, Supplement, Page e45, Abstract O101
